Why Black Diamond Therapeutics, Inc.’s (BDTX) Stock Is Down 5.23%
As of Tuesday, November 17, Black Diamond Therapeutics, Inc.’s BDTX share price has dipped by 5.23%, which has investors questioning if this is right time to buy.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Rosalio Madrigal
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
| Share Statistics | BDTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $75.9 | $203.5 | 21% |
|
| Shares Out (Mil) | 57.5 | 55.2 | 50% |
|
| Institutional Ownership | 98.9% | 93.3% | 83% |
|
| Float (Mil) | 52.6 | 40.4 | 47% |
|
| Beta | 3.46 | 1.05 | 98% |
|
| Avg Daily Volume (000s) | 797 | 569 | 66% |
|
| Price Change (52-week) |
(66.1%) | 38.8% | 15% |
|
| Growth | BDTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 18.5% | (10.7%) | 71% |
|
| EPS (5yr) | 17.0% | 15.4% | 63 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 40.5% | (15.7%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 6 | 6 | |
| Current EPS | ($0.202) | ($0.695) | ($0.990) | |
| Month Ago EPS | ($0.195) | ($0.567) | ($1.000) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.195) | ($0.567) | ($1.000) | |
| Year/Year Chg | 16.1% | (278.2%) | (336.9%) | |
| Financials | BDTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($44) | ($44) | 17% |
|
| EPS (TTM) | ($0.769) | ($1.400) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($33) | ($35) | 12% |
|
| Net Cash Flow (TTM) (Mil) | ($16) | $-0 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $12 | $4 | 29% |
|
| Enterprise Value (Q1) (Mil) | $7 | $142 | 7% |
|
| Valuation | BDTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.86 | 1.96 | 24% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BDTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (32.3%) | (47.0%) | 15% |
|
| ROE | (41.1%) | (51.8%) | 17% |
|
| Liabilities to Assets | 23.8% | 29.6% | 16% |
|
| F-Score | 2 | 3 | 7% |
|
Black Diamond Therapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors